The RPx platform is designed to have a unique dual local and systemic activity consisting of direct selective virus-mediated killing of the tumor resulting in the release of tumor derived antigens and altering of the tumor microenvironment to ignite a strong and durable systemic response. • Establish trusted partnerships with key stakeholders, including Medical Oncology, Surgical Oncology, Interventional Radiology, Radiation Oncology, Pharmacy, Nursing, Advanced Practice Providers, Care Coordinators, and Administrative Leadership.